Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies... Show more
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where RGEN declined for three days, in of 291 cases, the price declined further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on August 26, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on RGEN as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Aroon Indicator for RGEN entered a downward trend on August 15, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 67 cases where RGEN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for RGEN just turned positive on August 13, 2025. Looking at past instances where RGEN's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .
RGEN moved above its 50-day moving average on August 28, 2025 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for RGEN crossed bullishly above the 50-day moving average on August 22, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RGEN advanced for three days, in of 330 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. RGEN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.338) is normal, around the industry mean (10.933). RGEN's P/E Ratio (521.444) is considerably higher than the industry average of (58.441). RGEN's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.824). RGEN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.016). P/S Ratio (10.183) is also within normal values, averaging (38.282).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
a developer of biologic drugs
Industry PharmaceuticalsOther
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
PRRCX | 12.74 | 0.01 | +0.08% |
Victory Pioneer Equ Premium Income C | |||
MCSPX | 11.58 | -0.06 | -0.52% |
BlackRock Advantage SMID Cap Inv C | |||
VFINX | 597.26 | -3.80 | -0.63% |
Vanguard 500 Index Investor | |||
SSAQX | 79.71 | -0.55 | -0.69% |
State Street US Core Equity Fund | |||
USSCX | 33.42 | -0.52 | -1.53% |
Victory Science & Technology |
A.I.dvisor indicates that over the last year, RGEN has been closely correlated with DHR. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if RGEN jumps, then DHR could also see price increases.
Ticker / NAME | Correlation To RGEN | 1D Price Change % | ||
---|---|---|---|---|
RGEN | 100% | +0.12% | ||
DHR - RGEN | 67% Closely correlated | +0.26% | ||
A - RGEN | 66% Loosely correlated | +0.56% | ||
BIO - RGEN | 63% Loosely correlated | +1.43% | ||
MTD - RGEN | 61% Loosely correlated | +1.40% | ||
BLFS - RGEN | 59% Loosely correlated | +0.52% | ||
More |
Ticker / NAME | Correlation To RGEN | 1D Price Change % |
---|---|---|
RGEN | 100% | +0.12% |
RGEN (3 stocks) | 91% Closely correlated | -1.37% |
Pharmaceuticals (389 stocks) | 44% Loosely correlated | +0.22% |
Pharmaceuticals: Other (104 stocks) | 37% Loosely correlated | +0.57% |